Task: Answer Verification
Input (English): Question: Do long-term results from the Contura multilumen balloon breast brachytherapy catheter phase 4 registry trial?
Answer: Use of the CMLB for APBI delivery is associated with acceptable long-term local control and toxicity. Local recurrence-free survival was 97.8% at 3 years. Significant (grade 3) toxicity was uncommon, and no grade 4 toxicity was observed. Treatment at high-volume centers was associated with decreased late toxicity.
Output (English): yes